Agentic-AI driven Health, Performance, Life Science & Biotechnology Venture Capital
Cerdwen is a venture capital firm focused on the clinical and commercial acceleration of health, human performance, and biotechnology innovations.
Situated within a premier global life sciences corridor, we leverage nearly a century of collective clinical, operational and investment expertise.
Forward-thinking strategies challenging the status quo in biotechnology.
Transparency and ethical responsibility in all partnerships.
Exhaustive clinical and scientific due diligence for every potential investment.
Tangible advancements to global health through breakthrough therapies.
Partnering with founders from early validation through commercial deployment.
Championing diverse perspectives as essential drivers of innovation.
Serial entrepreneurs, physicians, and analysts accelerating breakthrough medical innovations.
Expert analysis on longevity, cardiology, and oncology from Cerdwen's investment team.
April 2026
Neurology and neurotechnology represent the next great investment frontier, with the global neuroscience market projected to exceed $38.9 billion by 2030. Over the next decade, we anticipate a structural convergence of brain-computer interface technology, next-generation neuroimaging, and RNA-based therapeutics that will transform how we treat Alzheimer's, Parkinson's, ALS, and treatment-resistant depression.
Read more →
March 2026
Longevity is undergoing a structural transition from "anti-aging" wellness to translational geroscience, with the global market projected to grow from $28.9 billion in 2025 to over $52.8 billion by 2035. We expect a shift toward "longevity infrastructure" where AI-driven drug discovery and epigenetic reprogramming move from managing symptoms to cellular rejuvenation.
Read more →
March 2026
Cardiology is undergoing its most significant transformation since the invention of the statin, driven by RNA-targeted therapeutics and the GLP-1 revolution. Over the next decade, we will transition from daily pill burdens to biannual "vaccine-like" injections that silence genes responsible for hypertension and hyperlipidemia.
Read more →
February 2026
In the next five to ten years, oncology will shift from "managing" systemic disease to "eradicating" it through molecularly-defined precision. We are moving beyond first-generation immuno-oncology into an era dominated by Antibody-Drug Conjugates and multi-specific antibodies that act as guided missiles.
Read more →
January 2026
Cerdwen is positioned to capture emerging capital opportunities in regenerative medicine as the global market is projected to reach $100 billion by 2030. We are focusing on cell and gene therapy manufacturing, iPSC-derived cell products, and bioprinting technologies that are moving from academic curiosity to clinical-stage readiness.
Read more →Cerdwen backs transformative companies at the frontier of health, longevity, and biotechnology.
Brain-computer interface platform targeting treatment-resistant neurological disorders with next-generation implantable devices.
Series A · 2025Epigenetic reprogramming platform leveraging AI-driven drug discovery to reverse cellular aging markers.
Seed · 2025RNA-targeted therapeutics for hypertension and hyperlipidemia with a biannual dosing profile.
Series B · 2024Antibody-drug conjugate platform with molecularly-defined precision targeting across solid tumors.
Series A · 2025iPSC-derived cell therapy manufacturing platform enabling scalable production of clinical-stage cell products.
Seed · 2026Precision biometrics and adaptive training platform for elite athletic performance optimization and injury prevention.
Series A · 2024